WO2007077818A1 - 不斉還元方法 - Google Patents
不斉還元方法 Download PDFInfo
- Publication number
- WO2007077818A1 WO2007077818A1 PCT/JP2006/325875 JP2006325875W WO2007077818A1 WO 2007077818 A1 WO2007077818 A1 WO 2007077818A1 JP 2006325875 W JP2006325875 W JP 2006325875W WO 2007077818 A1 WO2007077818 A1 WO 2007077818A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituent
- propionic acid
- diphenylphosphino
- cis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B53/00—Asymmetric syntheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
Definitions
- the present invention relates to a novel process for producing (2S) -2 benzil 3 (cis monohexahydr 2-isoindolinylcarbol) propionic acid or a salt thereof useful as a therapeutic agent for diabetes. More specifically, the present invention provides an asymmetric reduction of 2 benzylidene-3- (cis-hexahydro 2-isoindrylcarbol) propionic acid to produce (2S) -2 benzil 3- (cis hexahydro 2- This invention relates to a process for producing isoindole (carol) propionic acid or a salt thereof.
- mitiglinide Benzyl-3- (cis-hexahydro 2-isoindoleylcarpol) Propionic acid (hereinafter sometimes referred to as “mitiglinide”) or a salt thereof is an insulin release factor. Since it acts, it has a strong blood glucose lowering effect (see Patent Document 1).
- mitiglinide calcium hydrate product name: Glufast (registered trademark)
- Glufast registered trademark
- Patent Documents 7 and 8 As an asymmetric ligand in a rhodium complex compound for asymmetric reduction, one in which the phosphine moiety at the 4-position of pyrrolidine is dicyclohexylphosphine is known (see Patent Documents 7 and 8). There is also known a urea type having a t-butylaminocarbonyl group and the like as well as a force rubamate type having a t-butoxy carbonyl group and the like in BPPM as a substituent on the nitrogen atom of pyrrolidine (Patent Documents 7- 9).
- mitiglinide has a low melting point and is difficult to purify by recrystallization or the like, the development of a method capable of producing a benzylsuccinic acid derivative with the highest possible purity and optical purity in the production process is desired. It is rare.
- Patent Document 1 Japanese Patent Laid-Open No. 4-356459
- Patent Document 2 JP-A-6-340622
- Patent Document 3 JP-A-6-340623
- Patent Document 4 JP-A-5-170718
- Patent Document 5 Japanese Patent Laid-Open No. 4-330055
- Patent Document 6 Special Table 2002-507222
- Patent Document 7 Japanese Patent No. 2544926
- Patent Document 8 Japanese Patent No. 2617329
- Patent Document 9 Japanese Patent No. 2816555
- An object of the present invention is to provide a method for industrially producing mitiglinide having high optical purity.
- the present invention is directed to catalytic reduction of 2-benzylidene 3 (cis-hexahydro-2-isoindylcarbonyl) propionic acid in the presence of an asymmetric catalyst in which pyrrolidine bisphosphine compound and rhodium compound power are also prepared.
- the present invention relates to a process for producing (2S) —2-benzene-3 (cis-hexahydro-2isoindolecarbonyl) propionic acid.
- the present invention provides a reaction of (2S) -2-benzyl-1- (cis-hexahydro-2isoindole-l-carbonyl) propionic acid produced by the above-described method of the present invention with a basic substance such as calcium hydroxide.
- a basic substance such as calcium hydroxide.
- R 1 is an optionally substituted linear or branched alkyl group of 1 to C: a cycloalkyl group optionally having a substituent, or a substituent.
- R 2 and R 3 each independently represent an aryl group that may have a substituent, or an aryl group that may have a substituent. (The asterisk in the pyrrolidine ring indicates that the carbon atom at that position is in the S configuration.)
- Pyrrolidine bisphosphine compound represented by the following formula, and rhodium compound power:
- 2-benzylidene-3 cis-hexahydro-2 isoindoleyl carboyl
- propionic acid is catalytically reduced.
- (2S) 2 Benjirou 3 (cis-hexahydro 2-isoindoleylcar- ol) propionic acid.
- R 1 in the general formula (I) may have a substituent, a straight-chain or branched alkyl group having 1 to 10 carbon atoms; A lower cycloalkyl group having 3 to 7 carbon atoms; an optionally substituted monocyclic, polycyclic or condensed cyclic aryl alkyl group having 7 to 25 carbon atoms; or a substituent /, May! / Is a monocyclic, polycyclic or fused cyclic aryl group having 6 to 20 carbon atoms, and R 2 and R 3 each independently have a substituent.
- the method according to (1) above which is a monocyclic, polycyclic, or condensed cyclic aryl group having 6 to 20 carbon atoms.
- R 1 of the pyrrolidine bisphosphine compound represented by the general formula (I) has a linear or branched alkyl group having 1 to 10 carbon atoms and a alkenyl group as a substituent.
- R 2 and R 3 of the pyrrolidine bisphosphine compound represented by the general formula (I) each independently have an alkyl group or alkoxy group having 1 to 10 carbon atoms as a substituent.
- R 1 R 2 and R 3 in the pyrrolidine bisphosphine compound represented by the general formula (I) Substituent force of the alkyl group, cycloalkyl group, aralkyl group, or aryl group in the carbon atom 1 to 10
- Any one of the above (1) to (4), which is one or more groups selected The method described in 1.
- the pyrrolidine bisphosphine compound represented by the general formula (I) is represented by (2S, 4S) —N-phenylaminocarbol 4 diphenylphosphino 2 diphenylphosphinomethylpyrrolidine, (2S, 4S ) — N— 3, 4 Dichlorophenaminocarboru 4 Diphenylphosphino 2 Diphenylphosphinomethylpyrrolidine, (2S, 4S) — N— t-Butylaminocarbol 4 Diphenylphosphino 2 Diphenylphosphine Inomethylpyrrolidine, (2S, 4S) —N-Methylaminocarbolulu 4 Diphenylphosphino2 Diphenol Phosphinomethylpyrrolidine, (2S, 4S) —N—1S Phenylaminocarborolu 4 Diphenylphosphino 2 diphenylphosphinomethylpyrrolidine, (2S, 4S) — N — 1
- Rhodium compound power The method according to any one of (1) to (7) above, which is a rhodium complex having ethylene, 1,5 cyclooctagen or 2,5-norbornagen as a ligand.
- the alkyl group means a linear or branched lower alkyl group having 1 to 10 carbon atoms, preferably 4 to 10 carbon atoms.
- Specific examples of the alkyl group in the present invention include, for example, methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, s-butyl group, t-butyl group, n-pentyl group, isopentyl group, s- Examples include pentyl group, t-pentyl group, neopentyl group, hexyl group, heptyl group, octyl group, nonyl group, decyl group and the like.
- the cycloalkyl group means a lower cycloalkyl group having 3 to 7, preferably 5 to 7 carbon atoms.
- Specific examples of the cycloalkyl group in the present invention include, for example, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cyclohexyl group, and the like.
- an aryl group means a monocyclic, polycyclic or condensed cyclic aryl group having 6 to 20 carbon atoms, preferably 6 to 12 carbon atoms. More specifically, examples thereof include monocyclic, polycyclic, or condensed cyclic carbocyclic aromatic groups having 6 to 20 carbon atoms, preferably 6 to 12 carbon atoms. Specific examples of aryl in the present invention include a phenyl group and a naphthyl group.
- the aralkyl group means a monocyclic, polycyclic or condensed cyclic arylalkyl group having 7 to 25 carbon atoms, preferably 7 to 13 carbon atoms.
- the arylalkyl group in the present invention are preferably a alkylalkyl group, preferably a alkylalkyl group, such as benzyl group, 1-phenylethyl group, 2-phenylethyl group, ⁇ , ⁇ -dimethylbenzyl group and the like.
- the alkoxy group means a lower alkoxy group in which an oxygen atom is bonded to a linear or branched alkyl group having 1 to 10, preferably 1 to 7 carbon atoms.
- Specific examples of the alkoxy group in the present invention include, for example, methoxy group, ethoxy group, ⁇ -propyloxy group, isopropyloxy group and the like.
- a halogen atom means a fluorine atom, a chlorine atom, a bromine atom, and a hydrogen atom.
- the atomic power that is also a nuclear power means an atom that is chosen.
- Preferred examples of the halogen atom in the present invention include a chlorine atom and a bromine atom.
- the alkenyl group means a lower alkenyl group having 2 to 10 carbon atoms, preferably 2 to 6 carbon atoms.
- Specific examples of the alkenyl group in the present invention include, for example, a beryl group, an n probe group, an iso probe group and the like.
- the alkoxy carbo yl group is a lower alkoxy carbo yl group to which an oxycarbonyl group of a linear or branched lower alkyl group having 1 to 10 carbon atoms, preferably 1 to 7 carbon atoms, is bonded.
- an oxycarbonyl group of a linear or branched lower alkyl group having 1 to 10 carbon atoms, preferably 1 to 7 carbon atoms is bonded.
- Specific examples of the alkoxy carbo yl group in the present invention include a methoxy carbo ol group, an ethoxy carbo ol group, a t-butoxy carbo ol group and the like.
- the urea-type pyrrolidine bisphosphine compound used in the present invention has the following general formula (I)
- R 1 is an optionally substituted linear or branched alkyl group of 1 to C: LO, a cycloalkyl group optionally having a substituent
- R 2 and R 3 each independently represent an aryl group that may have a substituent, or an aryl group that may have a substituent. (The asterisk in the pyrrolidine ring indicates that the carbon atom at that position is in the S configuration.)
- the alkyl group, cycloalkyl group, aralkyl group and aryl group in the general formula (I) may have a substituent if necessary.
- a substituent include the aforementioned alkyl group, alkenyl group, One group or two or more groups selected from a group force consisting of a ruthel group, an alkoxy group, a halogen atom, and an alkoxycarbo yl group are exemplified. More specifically, alkyl Examples of the substituent that the group may have include a halogen atom, an alkoxy group, and an alkoxycarbonyl group.
- the substituent may be a cycloalkyl group, an aryl group or an aralkyl group, and examples of the substituent include a halogen atom, an alkyl group, an alkenyl group, an alkoxy group and an alkoxy group.
- R 1 in the general formula (I) has a lower alkyl group, a alkenyl group as a substituent, a phenylalkyl group, or a halogen atom as a substituent! /, Or phenyl group.
- the phenylalkyl group having an alkenyl group as a substituent include 1 (3 isopropylphenyl) 1 methylethyl group and the like.
- examples of the phenyl group having a halogen atom as a substituent include a 3,4-dichlorophenol group.
- R 2 or R 3 in the general formula (I) has an alkyl group or an alkoxy group as a substituent, and may be a phenyl group, more preferably a phenyl group. Groups.
- Preferred urea-type pyrrolidine bisphosphine compounds include, for example,
- DCPCPPM diphenylphosphinomethylpyrrolidine
- 2-benzylidene-3 (cis-hexahydride 2 isoindoleylcarbonyl) propionic acid which is a raw material compound in the method of the present invention, can be produced by the method described in Patent Document 6 and is limited to these methods. Is not to be done.
- the asymmetric catalyst used in the method of the present invention is one prepared by the optically active pyridine phosphine compound represented by the above general formula (I) and a rhodium compound, preferably a rhodium complex power, Preferred is a rhodium complex compound having an optically active pyrrolidine bisphosphine compound represented by the general formula (I) as a ligand.
- a rhodium complex compound is prepared according to the method described in any one of Patent Documents 8 to 9, for example, a urea-type pyridolysine bisphosphine compound represented by the general formula (I), a rhodium compound, Preferably, it can be easily prepared from a monovalent rhodium complex.
- rhodium compound and the preferred rhodium complex used in the preparation of the catalyst of the present invention, but examples of the rhodium complex include rhodium having ethylene, 1,5 cyclotagen or 2,5 norbornagen as a ligand. Complexes are preferred. Examples of such rhodium complexes include bis (ethylene) rhodium-chlor complex, (acetylylacetonato) (7? -1,5-cyclooctagen) rhodium complex, and (acetylylacetonato) dicarbo-rurodium complex.
- Rhodium 1,5 cyclooctadene chloro complex Rhodium 1,5 cyclooctadene chloro complex
- rhodium 1,5 cyclooctagen monotetrafluoroborate complex Rhodium 1,2, norbornagen-chlor complex
- rhodium-2,5-norbornager N-tetrafluoroboric acid complex rhodium-1,5-cyclocactogen-1-trifluoromethanesulfonic acid complex
- rhodium-1,5-cyclotactogen-1-hexafluorophosphate complex and the like.
- the rhodium complex may be supported on an insoluble solid surface such as silica gel or alumina. Examples thereof include CATAXAZ rhodium 1,5 cyclooctagen complex.
- the asymmetric catalyst comprises a pyrrolidine bisphosphine compound and a rhodium compound, preferably rhodium. It can be prepared by mixing the mu complex in a solvent. Alternatively, these may be mixed in a reaction solvent and directly prepared in the reaction system.
- the ratio of the rhodium compound to the pyrrolidine bisphosphine compound is 0.5 to 10 moles, preferably 1 to 5 moles per mole of rhodium atoms.
- the amount of rhodium metal in the asymmetric reaction is 1/2, 000 to 1Z100, 000 for 1 mol of rhodium metal per 1 mol of 2-benzylidene 3 (cis-hexahydro-2-isoindolecaryl) propionic acid.
- Mole preferably ⁇ is used at 1Z5,000 to lZ30,000, more preferably 1Z10000 to 1Z20000 mol. If this is shown by the molar ratio (SZC) of the substrate and the asymmetric catalyst, the SZC force is 2000 to 100,000, preferably 5000 to 30000, and more preferably 10,000 to 20000.
- the method of the present invention can also be carried out with a fixed catalyst.
- a fixed catalyst By using a fixed catalyst, the catalyst can be repeatedly used for asymmetric reduction as well as being easily separated.
- the asymmetric catalyst used for the fixed catalyst is preferably a fixed layer supported on a carrier such as silica gel or alumina.
- Preferred examples of the rhodium complex for preparing such a catalyst include CATAXAZ rhodium 1,5 cyclooctagen complex.
- the molar ratio (SZC) between the substrate and the asymmetric catalyst in the fixed catalyst is 1Z2 to about LZ10 in the case of a homogeneous catalyst system, for example, about 200 to 10,000, preferably about 500 to 5,000. However, it is not limited to this.
- Solvents used in the asymmetric reduction reaction according to the present invention include alcohols such as methanol, ethanol and isopropyl alcohol; mixed solvents of organic solvents such as toluene, tetrahydrofuran, acetone, methyl isobutyl ketone and chloroform, and alcohols. Or a mixed solvent of water and alcohols.
- the hydrogen pressure in the asymmetric reduction reaction is usually 0.1 to 15 MPa. 0.1-2 MPa, especially 0.2-2: LMPa is preferred.
- the reaction temperature is 0 to 150 ° C, preferably 10 to 100 ° C, particularly preferably about 10 to 50 ° C.
- the asymmetric catalyst of the present invention prepared from the pyrrolidine bisphosphine compound represented by the general formula (I) and the rhodium compound is a benzylidene-3 (cis-hexahydro) which is a raw material compound of the present invention.
- 2 Catalyst for isoindoleylcarpool) propionic acid
- the asymmetric catalyst of the present invention has 2 benzylidene 3 (cishexahydro 2-isoindolinylcarbol) propionic acid, which is the raw material compound of the present invention, and extremely excellent substrate specificity. It is thought that it is because. Therefore, the asymmetric reduction reaction of 2-benzylidene-3 (cishexahydro 2 isoindoleylcarbonyl) propionic acid with the asymmetric catalyst of the present invention is completed in a much shorter time than the ordinary asymmetric reduction reaction.
- the reaction time may be 0.5 to: L00 hours, 0.5 to 10 hours, preferably 2 to 20 hours, more preferably 2 to L0 hours. Many.
- a conversion rate of almost 100% can be achieved in a very short reaction time, and the target substance can be produced with high purity and high yield.
- the method for producing a salt of (2S) -2 benzyl-1-3- (cis-hexahydro-1-2-isoindylcarbonyl) propionic acid of the present invention can be carried out as a usual salt formation reaction. That is, it can be carried out by adding a basic substance such as calcium hydroxide to the free acid produced by the asymmetric reduction described above and stirring and mixing.
- a basic substance such as calcium hydroxide
- the solvent water, hydrous alcohol or the like can be used.
- This method can be carried out after isolating the free acid produced by the asymmetric reduction reaction described above.
- the method using the asymmetric reduction reaction of the present invention can produce a high-purity target product. Since the reaction mixture after completion of the asymmetric reduction without isolating the target product is diluted with water or alcohol as necessary, the basic substance is added directly to the reaction mixture. Can also be performed.
- the salt produced by the method of the present invention may be a hydrate containing crystal water.
- 2-benzylidene 3 (cishexahydro 2 isoindoleylcarbon) propionate has a high !, optical purity, a short time, and a small amount of catalyst. Can be manufactured.
- the method (1) was carried out at an SZC of 20000 and a reaction time of 16 hours.
- the residual ratio of the raw material in the high performance liquid chromatography was 1.27%, and the optical purity was 95.2% e.e.
- the residual ratio of propionic acid was 0.44%, and the optical purity of the obtained mitiglinide was 94.6% ee.
- the method (1) was carried out at an SZC of 20000 and a reaction time of 16 hours. As a result, we were unable to detect the raw material with high performance liquid chromatography. The optical purity of the product was 94.4% e.e.
- Example 3 The same procedure as in Example 1 was performed except that BCPPM 2.91 mg was used instead of PCPPM 3.02 mg in Example 1. After the reaction, 2 benzylidene-3- (cis-hexahydro 2-isoindolinylcarbol) propionic acid was not detected, and the optical purity of the obtained mitiglinide was 96.6% ee.
- Example 2 The same procedure as in Example 1 was performed except that SSR-C * PPM3.16mg was used instead of PCPPM3.02mg in Example 1. After the reaction, the residual ratio of 2 benzylidene-3- (cis-hexahydro-2-isoindolecarbonyl) propionic acid was 0.55%, and the optical purity of the obtained mitiglinide was 96.3% ee.
- Example 1 was performed except that 0000) was used. After the reaction, the residual ratio of 2-benzylidene 3 (cis-hexahydro 2 isoindoleylcarbonyl) propionic acid in the high performance liquid chromatography was 0.02%. The optical purity of the obtained mitiglinide is 9
- the method (1) was carried out at an SZC of 20000 and a reaction time of 16 hours. As a result, it was impossible to detect the raw material by high performance liquid chromatography. The optical purity of the product was 96.4% e.e.
- Example 10 Example 10
- Example 1 PCPPM 10.04 mg was used instead of PCPPM 3.02 mg, and rhodium 1,5 cyclooctagen monochlorine complex 1.
- CATAXAZ rhodium which is immobilized rhodium instead of 18 mg
- 2 benzylidene-3- (cis-hexahydro-2-isoindolecarbonyl) propionic acid was not detected, and the optical purity of the obtained mitiglinide was 95.5% ee.
- Example 1 was carried out in the same manner as Example 1 except that BPPM 2.92 mg was used instead of PCPPM 3.02 mg. After the reaction, the residual rate of 2 benzylidene-3- (cis-hexahydro-2-isoindylcarbol) propionic acid was 10.85%, and the optical purity of the obtained mitidalinide was 96. l% e.e.
- urea-type pyrrolidine bisphosphine compound as an asymmetric ligand is superior in both optical purity, reaction rate, and SZC compared to force rubamate-type pyrrolidine bisphosphine compound. . Therefore, the production method according to the present invention is an industrially excellent production method that enables high optical purity, shortening of reaction time, and reduction of the amount of catalyst.
- the method of the present invention comprises (2S) 2 benzil 3 (cis-hexahydro-2 isoindoleylcarpool) propionic acid or a salt thereof represented by the formula (I) useful as a therapeutic agent for diabetes.
- the present invention provides an efficient and high-purity new production method, is extremely useful in the pharmaceutical field, and has industrial applicability.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Catalysts (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06843259A EP1978016A4 (en) | 2005-12-27 | 2006-12-26 | PROCESS FOR ASYMMETRIC REDUCTION |
CN2006800492334A CN101346352B (zh) | 2005-12-27 | 2006-12-26 | 不对称还原方法 |
CA002634074A CA2634074A1 (en) | 2005-12-27 | 2006-12-26 | Asymmetric reduction method |
US12/087,092 US7847107B2 (en) | 2005-12-27 | 2006-12-26 | Asymmetric reduction method |
KR1020087017900A KR101437078B1 (ko) | 2005-12-27 | 2006-12-26 | 비대칭 환원방법 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-374989 | 2005-12-27 | ||
JP2005374989A JP4918257B2 (ja) | 2005-12-27 | 2005-12-27 | 不斉還元方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007077818A1 true WO2007077818A1 (ja) | 2007-07-12 |
Family
ID=38228171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/325875 WO2007077818A1 (ja) | 2005-12-27 | 2006-12-26 | 不斉還元方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7847107B2 (ja) |
EP (1) | EP1978016A4 (ja) |
JP (1) | JP4918257B2 (ja) |
KR (1) | KR101437078B1 (ja) |
CN (1) | CN101346352B (ja) |
CA (1) | CA2634074A1 (ja) |
RU (1) | RU2008130889A (ja) |
WO (1) | WO2007077818A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2616628C2 (ru) * | 2015-06-30 | 2017-04-18 | Открытое акционерное общество "Нефтяная компания "Роснефть" | Лиганд для получения комплекса переходного металла, способ его получения и способ получения комплекса переходного металла с использованием лиганда |
CN106008312B (zh) * | 2016-08-15 | 2018-06-29 | 河南中医学院 | 一种降糖药物米格列奈钙的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05170718A (ja) * | 1991-05-03 | 1993-07-09 | Hoechst Ag | 2(r)−ベンジルコハク酸モノアミド誘導体のエナンチオ選択的合成方法 |
JPH06340622A (ja) * | 1993-05-28 | 1994-12-13 | Kissei Pharmaceut Co Ltd | ベンジルコハク酸誘導体の製造方法およびその製造中間体 |
JP2002507222A (ja) * | 1997-07-03 | 2002-03-05 | アディール | ペルヒドロイソインドール置換体の製造方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4000113B2 (ja) | 2002-01-22 | 2007-10-31 | キッセイ薬品工業株式会社 | (3s)−3−メトキシカルボニル−4−フェニル酪酸金属塩およびその使用方法 |
-
2005
- 2005-12-27 JP JP2005374989A patent/JP4918257B2/ja not_active Expired - Fee Related
-
2006
- 2006-12-26 WO PCT/JP2006/325875 patent/WO2007077818A1/ja active Application Filing
- 2006-12-26 CA CA002634074A patent/CA2634074A1/en not_active Abandoned
- 2006-12-26 CN CN2006800492334A patent/CN101346352B/zh not_active Expired - Fee Related
- 2006-12-26 EP EP06843259A patent/EP1978016A4/en not_active Withdrawn
- 2006-12-26 KR KR1020087017900A patent/KR101437078B1/ko active IP Right Grant
- 2006-12-26 US US12/087,092 patent/US7847107B2/en not_active Expired - Fee Related
- 2006-12-26 RU RU2008130889/04A patent/RU2008130889A/ru not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05170718A (ja) * | 1991-05-03 | 1993-07-09 | Hoechst Ag | 2(r)−ベンジルコハク酸モノアミド誘導体のエナンチオ選択的合成方法 |
JPH06340622A (ja) * | 1993-05-28 | 1994-12-13 | Kissei Pharmaceut Co Ltd | ベンジルコハク酸誘導体の製造方法およびその製造中間体 |
JP2002507222A (ja) * | 1997-07-03 | 2002-03-05 | アディール | ペルヒドロイソインドール置換体の製造方法 |
Non-Patent Citations (3)
Title |
---|
AOKI K. ET AL.: "Immobilization of chiral phosphine ligands on silica gel by means of the allylsilane method and their use for catalytic asymmetric reactions", TETRAHEDRON: ASYMMETRY, vol. 15, no. 11, 2004, pages 1771 - 1777, XP004512326 * |
JENDRALLA H. ET AL.: "Short and efficient large scale synthesis of (R)-2-benzylsuccinic acid 4-[4-(BOC-amino)-1-piperidide] monoamide: N-terminal component of renin inhibitors by asymmetric hydrogenation", SYNLETT., no. 2, 1993, pages 155 - 157, XP003015083 * |
See also references of EP1978016A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1978016A1 (en) | 2008-10-08 |
JP4918257B2 (ja) | 2012-04-18 |
CN101346352A (zh) | 2009-01-14 |
KR101437078B1 (ko) | 2014-09-02 |
JP2007176824A (ja) | 2007-07-12 |
EP1978016A4 (en) | 2010-10-13 |
US7847107B2 (en) | 2010-12-07 |
CN101346352B (zh) | 2011-04-13 |
RU2008130889A (ru) | 2010-02-10 |
CA2634074A1 (en) | 2007-07-12 |
US20090043110A1 (en) | 2009-02-12 |
KR20080091152A (ko) | 2008-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007502315A (ja) | 共役ジエンのカルボニル化方法 | |
HU228925B1 (en) | Method for producing l-phenylephrine hydrochloride | |
WO2007077818A1 (ja) | 不斉還元方法 | |
WO2002070131A1 (fr) | Catalyseur metallique encapsule | |
CN109939737B (zh) | 卡宾钴催化剂、其制备方法及其在催化氢化醛和酮化合物中的应用 | |
JP4917064B2 (ja) | スルホニルイミデートのアリル化反応方法 | |
MX2012012938A (es) | Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable. | |
JP4413507B2 (ja) | ピンサー型金属錯体及びその製造方法、並びにピンサー型金属錯体触媒 | |
JPH1095792A (ja) | ルテニウム−ホスフィン錯体の製造方法 | |
WO2001036359A1 (fr) | Derive de binaphtol fluore actif optiquement | |
CN112675920A (zh) | 一类单手性中心催化剂及其制备和催化合成手性醇类化合物和手性α-烯丙醇的方法 | |
JP5001263B2 (ja) | ジフェニルアラニン誘導体作製のための不斉水素化 | |
JP3691235B2 (ja) | 光学活性ピペリジン類の製造方法 | |
JP2004269522A (ja) | 新規なルテニウム錯体、その製造方法、及びそれを用いたアミド化合物の製造方法 | |
JP2981621B2 (ja) | ビフェニルビスホスフィン錯体 | |
CN108046979B (zh) | 一种高效制备碘化苄及其衍生物的方法 | |
KR100565763B1 (ko) | 케톤의 제조방법 | |
JP2001002610A (ja) | 光学活性アルコールの製造方法及び遷移金属錯体 | |
CN118620007A (zh) | 一种手性四齿膦配体化合物及其制备方法和应用 | |
JP4257414B2 (ja) | ホスフィンの遊離方法 | |
JP2000247990A (ja) | フェロセニルアミノホスフィン及び該ホスフィンを含む触媒 | |
JP4572389B2 (ja) | 光学活性ホスホン酸エステル類の製造方法 | |
CN113200884A (zh) | 一种手性羧酸化合物及其合成方法及应用 | |
JP2002241344A (ja) | 光学活性アルコールの製造方法 | |
CN116063347A (zh) | 一类手性苯环骨架的膦-1,2-二苯基乙二胺配体及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680049233.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2634074 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/008526 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087017900 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006843259 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008130889 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12087092 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: PI0620771 Country of ref document: BR |
|
ENPW | Started to enter national phase and was withdrawn or failed for other reasons |
Ref document number: PI0620771 Country of ref document: BR Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL POR NAO ATENDER AS DETERMINACOES REFERENTES A ENTRADA DO PEDIDO NA FASE NACIONAL E POR NAO CUMPRIMENTO DA EXIGENCIA FORMULADA NA RPI NO 2479 DE 10/07/2018. |